Can a new injection tame the painful lumps of hidradenitis suppurativa?

NCT ID NCT07766005

Not yet recruiting Disease control Sponsor: Spyre Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Aug 14, 2026 · Last updated Aug 14, 2026

Summary

This phase 2 trial tests whether an investigational medicine called SPY072 can improve hidradenitis suppurativa (HS), a chronic skin condition causing painful lumps and tunnels. About 150 adults with moderate-to-severe HS who are already receiving standard care will be randomly assigned to receive SPY072 or a placebo for 16 weeks. The study will measure how many participants achieve a significant reduction in their HS lesions and will monitor safety and how long any benefits last.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SPY072, an investigational medicine given as an injection under the skin
What this could lead to: If successful, SPY072 could offer a new treatment option for people with moderate-to-severe hidradenitis suppurativa, potentially reducing painful lumps and improving quality of life.
What could go wrong: This is an early-phase trial with a small number of participants, so results may not be conclusive. The medicine may not work better than placebo, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIDRADENITIS SUPPURATIVA (HS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hidradenitis hidradenitis suppurativa Skin and Connective Tissue Diseases skin disorder sweat gland disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIDRADENITIS SUPPURATIVA (HS)

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Site 100

Bowling Green, Kentucky, 42104, United States
Site 101

Indianapolis, Indiana, 46250, United States
Site 102

New York, New York, 10023, United States
Site 103

Boston, Massachusetts, 02115, United States
Site 104

The Bronx, New York, 10455, United States
Site 105

Dallas, Texas, 75246, United States
Site 106

Mill Creek, Washington, 98012, United States
Site 107

Tyler, Texas, 75703, United States
Site 108

Baton Rouge, Louisiana, 70809, United States
Site 109

Mt. Pleasant, South Carolina, 29464, United States
Site 110

New Orleans, Louisiana, 70115, United States
Site 111

Irvine, California, 92614, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.